29 January 2024
RUA Life
Sciences Plc
("RUA Life Sciences",
the "Company" or the
"Group")
Directorate Change
RUA Life Sciences (AIM: RUA),
the holding company of a group of medical device businesses focused
on the exploitation of the world's leading long-term implantable
biostable polymer (Elast-Eon™), announces
that with immediate effect Caroline Stretton, Group Managing
Director, has resigned as a director of the Company and is leaving
her role as Group Managing Director to pursue other business
opportunities.
The executive directors will
continue to manage the Company supported by the non-executive
directors. The Board is considering the appropriate longer
term management structure of the Company and further announcements
will be made in due course, as appropriate.
Bill Brown, Chairman of RUA, said:
"The Board of RUA thanks Caroline for her hard work over the last
year and wishes her well for the future. RUA is pursuing a
number of opportunities to develop the business further and these
will play a part in the future shape of the senior leadership team.
Current trading remains in line with the Board's
expectations."
For
further information contact:
|
RUA
Life Sciences
Bill Brown, Executive
Chairman
Lachlan Smith, Chief Financial
Officer
|
Tel: +44 (0)1294
317073
|
|
Cavendish Capital Markets
Limited
(Nominated Adviser and Broker)
Giles Balleny/Dan
Hodkinson (Corporate Finance)
Charlie
Combe (Broking)
Michael
Johnson (Sales)
|
Tel: +44 (0)20 7220 0500
|
About RUA Life Sciences
The RUA Life
Sciences group was created in April
2020 when RUA Life Sciences Plc (formerly known
as AorTech International Plc) acquired RUA Medical
Devices Limited to create a fully formed medical device
business. RUA Life Sciences is the holding company of the
Group's four trading businesses, each exploiting the Group's
patented polymer technology.
Our vision is to improve the lives
of millions of patients by enabling medical devices with
Elast-EonTM, the world's leading long-term implantable
polyurethane. Whether it is licensing Elast-EonTM,
manufacturing a device or component, or developing next generation
medical devices, a RUA Life Sciences business is pursuing
our vision.
Elast-Eon™'s biostability is
comparable to silicone while exhibiting excellent mechanical, blood
contacting and flex-fatigue properties. These polymers can be
processed using conventional thermoplastic extrusion and moulding
techniques. With over 8 million implants and 15 years of successful
clinical use, RUA's polymers are proven in long-term life enabling
applications.
The Group's four business units
are:
|
RUA
Contract Manufacture:
|
End-to-end contract developer and
manufacturer of medical devices and implantable fabric
specialist.
|
|
RUA
Biomaterials:
|
Licensor of
Elast-EonTM polymers to the medical device
industry.
|
|
RUA
Vascular:
|
Commercialisation of open surgical
vascular grafts and patches
|
|
RUA
Structural Heart:
|
Development of polymeric leaflet
systems for heart valves.
|